1. Nutex Health faces a class action lawsuit for misleading investors. 2. Investors who suffered losses between August 2024 and August 2025 can join. 3. Allegations include deception about revenue sustainability and internal controls. 4. Company's public statements were deemed false and materially misleading. 5. Market reactions likely caused investor damages when facts were revealed.
The allegations of fraud, if substantiated, may lead to a significant loss of investor trust and market value, similar to historical cases like Valeant Pharmaceuticals' scandal in 2015.
Legal challenges in the form of class action lawsuits significantly affect company valuation and investor behavior, increasing the likelihood of stock price fluctuation.
Ongoing litigation and potential financial fallout typically impact stock price swiftly, often observed in similar cases such as Enron's downturn.
The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Nutex Health Inc. ("Nutex" or "the Company") (NASDAQ: NUTX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Investors who purchased the Company's securities between August 8, 2024 and August 14, 2025, inclusive (the "Class Period"), are encouraged to contact the firm before October 21, 2025.
If you are a shareholder who suffered a loss, click here to participate.
We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at bschall@schallfirm.com.
The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.
According to the Complaint, the Company made false and misleading statements to the market. Nutex engaged in a coordinated scheme with HaloMD to defraud insurance companies. The Company's revenue attributable to its engagement with HaloMD was unsustainable. The Company overstated its ability to build and maintain robust internal controls over internal reporting. The Company failed to properly calculate stock-based compensation obligations. Based on these facts, the Company's public statements were false and materially misleading throughout the class period. When the market learned the truth about Nutex, investors suffered damages.
Join the case to recover your losses
The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250825464928/en/
The Schall Law Firm
Brian Schall, Esq.,
www.schallfirm.com
Office: 310-301-3335
info@schallfirm.com